0 0

Cited 0 times in

기능성 소화불량증 환자에 대한 서방형 UIC201609/UIC201610 병용요법의 유효성 및 안전성을 비교평가하기 위한 다기관, 무작위배정, 위약대조 임상시험: 예비 보고

Other Titles
 Multicenter, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Controlled-release, Once-daily UIC201609/UIC201610 Combination Therapy for Functional Dyspepsia: Preliminary Study 
Authors
 이정원  ;  윤영훈  ;  최석채  ;  이광재  ;  김나영 
Citation
 Korean Journal of Gastroenterology, Vol.77(4) : 171-178, 2021-02 
Journal Title
 Korean Journal of Gastroenterology 
ISSN
 1598-9992 
Issue Date
2021-02
Keywords
Functional dyspepsia ; Mosapride ; Patient safety ; Stomach ; Treatment outcome
Abstract
Backgrounds/aims: Functional dyspepsia is a disease involving a range of upper gastrointestinal symptoms derived from various pathophysiologies. Tablets containing a combination of rabeprazole and controlled-release (CR) mosapride were recently developed. To investigate a more effective treatment, this trial evaluated the efficacy and safety of UIC201609/UIC201610 as a preliminary study. Methods: A multicenter, double-blind, randomized study was performed on 30 subjects. UIC201609/UIC201610 (combination of rabeprazole and CR mosapride) was the case group, and the two control groups were rabeprazole 10 mg once a day and mosapride 15 mg CR tablet once a day. As a primary efficacy endpoint of the study, the changes in the total score of eight items of the Nepean Dyspepsia Index-Korean version were analyzed at 2 weeks and 4 weeks. The outcomes regarding safety were collected. Results: The total symptom score of Nepean Dyspepsia Index-Korean decreased in the rabeprazole single group (29.4±17.1), mosapride CR single group (33.4±15.6), and UIC201609/UIC201610 group (33.4±11.8) at 4 weeks without significant differences. On the other hand, the UIC201609/UIC201610 combination group showed more score reduction of pain in the upper abdomen, burning in the upper abdomen compared to each control group, but it did not reach statistical significance. No difference was found in safety analysis. Conclusions: UIC201609/UIC201610 once daily showed some improvement in epigastric pain and dyspepsia in patients with functional dyspepsia, but there was no significance. Further study based on the advanced clinical trial design will be needed to confirm the efficacy of UIC201609/UIC201610 combination therapy in the future.
Files in This Item:
T202101591.pdf Download
DOI
10.4166/kjg.2020.171
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Youn, Young Hoon(윤영훈) ORCID logo https://orcid.org/0000-0002-0071-229X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182930
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links